Study Protocol: Phase‐Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors

[1]  Young Hak Kim,et al.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.

[2]  Ashley V. Menk,et al.  Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia , 2016, Cancer Immunology Research.

[3]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[4]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[5]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[6]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  H. Udono,et al.  Immune-mediated antitumor effect by type 2 diabetes drug, metformin , 2015, Proceedings of the National Academy of Sciences.

[8]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[9]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[10]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[11]  A. Gemma,et al.  F1000 highlights , 2010 .

[12]  K. Kiura,et al.  Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. , 2007, Oncology reports.

[13]  K. Matsuo,et al.  Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .